Featured news | Nanologica

Bulletin from the Annual General Meeting of Nanologica AB (publ)

2 June, 2022

Today June 2nd, 2022, Nanologica AB (publ) held its annual general meeting for the financial year 2021, where the following resolutions were passed. Adoption of income statement and balance sheet for the financial year 2021 and disposition of result The annual general meeting adopted the income statement and balance sheet for the company and for the group in accordance with the presented accounting documents, and resolved, in accordance with the board’s proposal, that the accumulated

CEO Andreas Bhagwani presenting At Naventus Healthcare Summit May 10, 2022

11 May, 2022

Introducing NLAB Saga®- a new generation silica for preparative chromatography

9 May, 2022

We are officially launching NLAB Saga® – Nanologica’s silica for preparative chromatography! NLAB Saga was developed with a clear goal in mind – to increase the availability of better and cheaper peptide and oligonucleotide-based medicines to a larger number of patients across the world, for the betterment of mankind. NLAB Saga has been specifically developed to meet the strict requirements of industrial scale purification by chromatography. Due to its exceptional mechanical and chemical stability, NLAB

Kallelse till årsstämma i Nanologica AB (publ)

4 May, 2022

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 2 juni 2022, klockan 12.00, i The Parks lokaler på Magnus Ladulåsgatan 1, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 24 maj 2022, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast måndagen den 30

Vd Andreas Bhagwani presenterar första kvartalet

29 April, 2022

Nanologica’s Interim Report Jan-Mar 2022

29 April, 2022

PERIOD IN BRIEF FINANCIAL SUMMARY Net sales for the first quarter amounted to TSEK 270 (5,622) The operating result amounted to TSEK -15,592 (-6,768) Result after tax amounted to TSEK -15,915 (-7,845) Earnings per share before and after dilution were SEK -0.57 (-0.28) Cash and cash equivalents amounted to TSEK 3,969 (57,069) as per March 31, 2022 SIGNIFICANT EVENTS IN THE FIRST QUARTER In January, a credit facility of up to MSEK 50 was signed

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.